ArticleCureus2024
Modulation of Inflammation in McCoy Cells by Zinc Nanoparticles Conjugated With β-Chitosan.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual pathway activation in wound repair: An in vitro study of betanin and theaflavin on periodontal ligament fibroblasts.Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study investigated biosynthetically derived β-chitosan-derived zinc nanoparticles (β-Ch-Zn NPs) for their potential anti-inflammatory properties on McCoy cells. β-Ch-Zn NPs were synthesized using a green chemistry approach, and their characterization confirmed successful synthesis, appropriate size, and morphology. The study aimed to evaluate the cytotoxicity of β-Ch-Zn NPs and their effects on inflammatory responses in McCoy cells stimulated with lipopolysaccharide (LPS).
methodsβ-Ch-Zn NPs were synthesized and characterized using Fourier-transform infrared spectroscopy (FTIR), ultraviolet-visible spectroscopy (UV-Vis) spectroscopy, and X-ray diffraction (XRD) to confirm their structural and morphological properties. The cytotoxicity of β-Ch-Zn NPs was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay at various concentrations to determine safe doses for subsequent experiments. To induce inflammation, McCoy cells were pretreated with β-Ch-Zn NPs at different concentrations before LPS stimulations. Gene expression analysis using quantitative real-time polymerase chain reaction was performed to measure the messenger RNA (mRNA) levels of proinflammatory cytokine.
resultsFTIR, UV-Vis spectroscopy, and XRD confirmed the successful synthesis of β-Ch-Zn NPs with the desired size and morphology. The MTT assay demonstrated concentration-dependent cytotoxicity of β-Ch-Zn NPs, indicating safety for cellular studies. Pretreatment with β-Ch-Zn NPs significantly downregulated the mRNA expression of proinflammatory cytokines. The nanoparticles effectively downregulate proinflammatory cytokines and promote anti-inflammatory pathways, as evidenced by the significant reduction in interleukin (IL)-2, IL-6, hypoxia-inducible factor, and nuclear factor kappa B expression in a dose-dependent manner.
conclusionsThis study demonstrated that biosynthetically derived β-Ch-Zn NPs exhibit potent anti-inflammatory effects in McCoy cells. These findings underscore the therapeutic potential of β-Ch-Zn NPs for treating inflammatory conditions and support further investigation into their in vivo efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.